Bioventus (NASDAQ:BVS) Sees Strong Trading Volume – Should You Buy?

Shares of Bioventus Inc. (NASDAQ:BVS) saw unusually-strong trading volume on Wednesday . Approximately 489,148 shares traded hands during trading, a decline of 4% from the previous session’s volume of 506,912 shares.The stock last traded at $14.51 and had previously closed at $13.42.

Wall Street Analyst Weigh In

BVS has been the topic of several research analyst reports. Weiss Ratings reiterated a “hold (c)” rating on shares of Bioventus in a research note on Tuesday, June 2nd. Barrington Research reissued an “outperform” rating and issued a $14.00 target price on shares of Bioventus in a research report on Tuesday, June 30th. Finally, Canaccord Genuity Group restated a “buy” rating and issued a $15.00 target price on shares of Bioventus in a research note on Tuesday, June 16th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $14.75.

Bioventus Stock Up 11.8%

The stock’s 50 day moving average is $10.47 and its 200 day moving average is $9.56. The company has a market capitalization of $1.25 billion, a PE ratio of 36.51, a PEG ratio of 1.72 and a beta of 0.63. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.13 and a current ratio of 1.69.

Bioventus (NASDAQ:BVS) last issued its earnings results on Wednesday, August 5th. The company reported $0.22 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.22. The business had revenue of $153.21 million for the quarter. Bioventus had a net margin of 4.94% and a return on equity of 29.97%. Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. On average, sell-side analysts anticipate that Bioventus Inc. will post 0.79 EPS for the current fiscal year.

Institutional Trading of Bioventus

Institutional investors have recently added to or reduced their stakes in the stock. Bank of America Corp DE boosted its stake in Bioventus by 40.3% in the 1st quarter. Bank of America Corp DE now owns 86,057 shares of the company’s stock worth $786,000 after purchasing an additional 24,723 shares during the period. Engine Capital Management LP bought a new stake in shares of Bioventus during the first quarter valued at about $2,876,000. Quantinno Capital Management LP increased its position in shares of Bioventus by 119.6% during the first quarter. Quantinno Capital Management LP now owns 72,023 shares of the company’s stock valued at $658,000 after buying an additional 39,222 shares during the period. Lazard Asset Management LLC lifted its holdings in shares of Bioventus by 12.9% in the first quarter. Lazard Asset Management LLC now owns 305,517 shares of the company’s stock worth $2,789,000 after buying an additional 35,008 shares in the last quarter. Finally, Sei Investments Co. boosted its position in shares of Bioventus by 160.7% in the first quarter. Sei Investments Co. now owns 289,648 shares of the company’s stock valued at $2,644,000 after acquiring an additional 178,539 shares during the period. Hedge funds and other institutional investors own 62.94% of the company’s stock.

Bioventus Company Profile

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.